Newsroom

Find the latest news from Allurion, including press releases, media coverage and multimedia content

News Coverage

ALLURION FOR WEIGHT LOSS

Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination With Compute Health

Weight Loss Device Maker Nears Deal with Medtronic Ex-CEO’s SPAC

Video - Sustainable solutions to handle the rising issue of obesity

Cedric Damour - PR Manager

cdamour@allurion.com

+33 7 84 21 02 20

* Ienca et al. Obes Surg. 2020 2. Vantanasiri et al. Obes Surg 2020.
** Ienca, Presented at TOS Obesity Week, 2020.
*** In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal.
**** The Allurion Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurion advises a 6-month follow-up. Its duration is defined by the physician and may vary depending on the physician and patient profile.

Quote from Lucy Jones, dietician http://www.lucyjonesdietitian.co.uk
Clinical Trial Reports: DAA069 and DAA105
Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.
Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.
Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.
Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.
Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1
Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.
Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA
Genco et al. Abstract A185. Oral Presentation at Obesity Week, 2018, Nashville, USA
Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States
Ienca et al. Presented at TOS 2020
Please read the Elipse balloon IFU for further information: https://www.eifu.online/LAB/02
Ienca et al. Accepted abstract at Obesity Week 2020

Hi, I am Ally!
How can I help you?

Chat with Ally